Administering CAR-T Cells Post Transplantation to Target Acute Myeloid Leukemia with Dr. Guenther Koehne Baptist Health Miami Cancer Institute

Dr. Guenther Koehne is the Deputy Director and Chief of Blood and Marrow Transplant and Hematologic Oncology at the Baptist Health South Florida Miami Cancer Institute. They are part of a clinical trial for an approach that protects healthy cells from the toxic side-effects of targeted blood cancer treatments with a focus on acute myeloid leukemia (AML). Guenther explains," And then, we have the opportunity to administer medications or CAR-T cells, for example, post transplantation, that are specifically targeting CD33, which then presumably allows us to specifically target residual leukemia cells." "So, my institution, Miami Cancer Institute, and before that, I was at Memorial Sloan Kettering Cancer Center, where I implemented the purification of stem cells from the stem cell product, from the donor stem cell product, allowing to deplete the T cells and other cells that were not necessarily needed for a successful transplant while we have a purified stem cell population. And on this clinical trial, we can now use the purified stem cells and send them to a specified laboratory to silence or down regulate the expression of CD33, using CRISPR technology so that the end product after this step will include a donor-derived stem cell population that is CD33 negative." #MiamiCancerInstitute #VorBio #CellTherapy #BloodCancers #AML #AcuteMyeloidLeukemia #AML #Leukemia #ClinicalTrial #Miami miamicancerinstitute.com Download the transcript here